JPRN-jRCT2080221240未知2 期
Phase II clinical study of RG3502 in HER2 positive patients with locally advanced/recurrent or metastatic breast cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Inoperable, locally advanced/recurrent or metastatic breast cancer
- •- HER2-positive (FISH + or IHC 3+)
- •- ECOG PS :0-2
排除标准
- •- Clinically significant cardiac disease
- •- Grade 3 or higher Hypersensitivity to trastuzumab
研究者
相似试验
尚未招募
不适用
Efficacy analysis of anti-HER2 treatment in HER2-enriched early breast cancer identified by PAM50KCT0006154Yonsei University Health System, Gangnam Severance Hospital59
招募中
不适用
A Phase II trial of preoperative HER2 targeting and endocrine therapy in postmenopausal women with HER2 and HR positive breast cancerNeoplasmsKCT0001583Yonsei University Health System, Gangnam Severance Hospital132
进行中（未招募）
1 期
DetectIV - Treatment of patients with advanced metastatic breast cancer and circulating blood cells devoid of Her2/neu.EUCTR2013-001269-18-DEniversitätsklinikum Ulm (AöR)300
未知
1 期
Phase I of RG3502 in Combination With RG1273HER2 positive Breast CancerJPRN-jRCT2080221197Chugai Pharmaceutical Co., Ltd.6
进行中（未招募）
不适用
Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy - Phase II in Trastuzumab FailuresThe medical condition under investigation is HER-2 positive metastatic breast cancer. Patients will have progressed on, or be intolerant of, treatment with trastuzumab (Herceptin).MedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2007-004805-80-GB40